1152475-42-7

Usage

Uses

Used in Pharmaceutical Applications:
7-Bromo-2-chlorothieno[3,2-d]pyrimidine is used as a building block for the synthesis of various biologically active molecules. Its unique structure and chemical properties contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Applications:
In the agrochemical industry, 7-Bromo-2-chlorothieno[3,2-d]pyrimidine serves as a key component in the creation of compounds with pesticidal or herbicidal properties. Its incorporation into these molecules can enhance their effectiveness in controlling pests and weeds.
Used in Research and Development:
7-Bromo-2-chlorothieno[3,2-d]pyrimidine is utilized in the research and development of new drugs and materials. Its presence in experimental compounds allows scientists to explore its potential interactions and reactions, leading to the discovery of novel therapeutic agents and innovative materials.

Upstream product

• 1119280-68-0 2-chlorothieno[3,2-d]pyrimidine 
• 16234-14-3 2,4-dichlorothieno[3,2-d]pyrimidine 
• 1293987-55-9 7-bromo-2-chloro-3,4-dihydrothieno[3,2-d]pyrimidine 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 41102-25-4 7-bromo-2,4-dichloroimidazo[2,1-f][1,2,4]triazine 
• 41102-02-7 7-bromothieno[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 

Downstream Products

• 1152475-66-5 2-chloro-7-phenylthieno[3,2-d]pyrimidine 
• 1152474-52-6 7-bromo-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1293987-56-0 3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)benzenamine 
• 1293987-77-5 2-chloro-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-7-amine 
• 1293987-76-4 N-(3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)phenyl)-N-methylmethanesulfonamide 
• 1293987-54-8 N-(3-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-ylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide hydrochloride 
• 1293987-57-1 N-(3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)phenyl)-methanesulfonamide 
• 1293987-05-9 N-(3-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-ylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide 
• 1313036-45-1 N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-7-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1313036-46-2 7-(3-aminophenyl)-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)thieno[3,2-d]pyrimidin-2-amine 
• 1313036-25-7 N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acrylamide 

Relevant academic research and scientific papers

Identification of Thieno[3,2- d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3

Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2-d]pyrimidine derivatives. An intensive structure-activity relationship (SAR) study led

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comp

COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH

Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.

2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comp

N-CONTAINING HETEROCYCLIC COMPOUNDS

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.